Bioequivalence Study of Bafiertam 190 mg and Vumerity® 462 mg Delayed-Release Capsules in Fasting Healthy Subjects
Status:
Completed
Trial end date:
2021-08-27
Target enrollment:
Participant gender:
Summary
A single-dose, randomized, open-label, two-way crossover, two-period, two-sequence,
two-treatment, single-center, bioequivalence study of Bafiertam and Vumerity.